Portfolio News

 

   
June 24, 2016
Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement
Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement   --Transaction forms combined NASDAQ-listed biopharmaceutical company, focused on the discovery, development and commercialization of plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME)   --KalVista to become a wholly owned subsidiary of Carbylan, and KalVista shareholders to become majority owners of Carbylan upon the closing ...

Read more

Team - Kate Bingham
June 3, 2016
Dementia Discovery Fund invests in Gen2 Neuroscience Ltd
  Gen2 is a start-up drug discovery company seeking to develop drugs that target toxic tau species that cause pathology in dementia, thereby slowing disease progression.   London and Boston, 3 June 2016 - The Dementia Discovery Fund, managed by SV Life Sciences, is an innovative global investment fund launched in October 2015 to develop disease modifying drugs for dementia, announces an investment in new drug discovery company Gen2 Neuroscience Ltd.

Read more

April 15, 2016
LifeSci Advisors Announces Comprehensive Action Plan to Advance Gender Diversity in the Life Sciences Industry
NEW YORK, April 15, 2016 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today a comprehensive plan to address the lack of gender diversity in the life sciences industry. The company has partnered with pioneering organizations Women in Bio and Girls Inc. of New York City to provide mentorship and advancement programs for women and girls in the STEM (science, technology, engineering, and math) fields, created an advisory board of ...

Read more

April 15, 2016
SV Life Sciences and Health Enterprise Partners Announce Formation of Jet Health
Accomplished healthcare executive Jim Glynn to lead home healthcare platform For Immediate Release Irvine, CA, April 15, 2016 – SV Life Sciences Advisers (“SVLS”) and Health Enterprise Partners (“HEP”) announced today that they have partnered with experienced healthcare services executive Jim Glynn to form Jet Health, Inc. (“Jet Health”).

Read more

Team - James Garvey
September 3, 2015
Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering
DUBLIN and ALISO VIEJO, Calif., Sept. 3, 2015 /PRNewswire/ -- Allergan plc AGN, -0.45% a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction.

Read more

July 31, 2015
FDA Approval of ReShape™ Dual Balloon Marks Significant Step for the Weight Loss Program in Helping at Risk Group of Patients
Obesity is on the rise and is a worldwide epidemic. A recent Lancet study noted that the chance of an obese person becoming normal weight is less than .5%. Currently in the United States, the obese population outnumbers the overweight population. Bariatric surgery helps patients with severe obesity in terms of weight loss, reduction in severity and number of comorbid conditions. This week the U.S.

Read more

January 2015
Entellus Medical - IPO
SV Life Sciences Advisers notes that Entellus Medical successfully listed on NASDAQ on 29 January 2015 The business wire press release is below Nasdaq Welcomes Entellus Medical, Inc. (Nasdaq: ENTL) to The Nasdaq Stock Market NEW YORK, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company, commenced on The Nasdaq Stock Market on January 29, 2015.

Read more

Team - Paul LaViolette, David Milne
January 2015
Sale of Convergence Pharmaceuticals
SV Life Sciences Fund V notes that Biogen Idec (NASDAQ: BIIB) acquired Convergence from its owners, SV Life Sciences and others, for a possible total of $675m - $200m upfront and $475m of milestone based payments.  Convergence Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for chronic pain.  Biogen Idec Press release   ...

Read more

Team - Kate Bingham
December 2014
Oncoethix Exit
SV Life Sciences Fund V notes that Merck acquired Oncoethix from its owners, SV Life Sciences and others, for an upfront payment of $110m. Additional milestone payments of up to $265m are contingent upon clinical and regulatory events being achieved. Oncoethix is a clinical stage biotechnology company developing innovative cancer drugs. . Merck Press Release ...

Read more

Team - Kate Bingham, Michael Carter
July 8, 2014
Michael Balmuth Joins SV Life Sciences as Partner
Michael Balmuth Joins SV Life Sciences as Partner Firm Adds Deep Healthcare IT Experience to Healthcare Services Team   BOSTON, MA; SAN FRANCISCO CA; LONDON, UK (July 8, 2014): SV Life Sciences ("SVLS"), a leading, international life sciences venture capital firm, today announced the appointment of Michael Balmuth as Partner.   Mr. Balmuth joins SVLS’ Healthcare Services team, a highly experienced group that looks to partner with accomplished management teams with ...

Read more

June 2, 2014
SV Life Sciences Appoints Three New Venture Partners
Firm Adds Significantly to Strength of Biotech Investment Team   BOSTON, MA, SAN FRANCISCO, CA, LONDON, UK (June 2, 2014): SV Life Sciences ("SVLS"), a leading international life sciences venture capital firm, today announced the appointments of Dan Burgess, Dr. Ed Mascioli and Dr. Michael Mendelsohn as new venture partners.   All three new venture partners will join SVLS’ biotechnology investment team, a highly experienced group investing in truly innovative ...

Read more

May 2014
Urgent Team Holdings
SV Life Sciences Fund V invested in Urgent Team Holdings (UTH) as part of a $10.2m series B financing round. UTH own and operate a regional network of urgent care facilities in the Southern United States.   ...

Read more

Team - Tom Flynn, Eugene Hill
May 2014
Kalvista Pharmaceuticals - Investment
SV Life Sciences Fund IV invested in Kalvista as part of a $5.2m Series A2 extension financing round. Kalvista is a Pharmaceutical and Ophthalmology company developing Plasma Kallikrein inhibitors.   ...

Read more

Team - Kate Bingham, Graham Boulnois
May 2014
Avitide
SV Life Sciences Fund V invested in Avitide as part of a $3.4m Series B financing round. Avitide is a biopharmaceutical company dedicated to the discovery and development of affinity purification products that will improve the fundamental timeframes and economics of commercial bioprocessing.   ...

Read more

Team - Michael Ross

⇧ Back to top